undamentalytics Newsletter
Sign in

TG Therapeutics, Inc. balance sheet

At the end of fiscal 2025, TG Therapeutics, Inc. had total assets of $1.06bn, total liabilities of $415m and shareholders' equity of $648m. It held $79.1m in cash against $246m of debt: net debt of $166m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2557421135532991029318079483
Receivables—————1051129306402
Inventory——————040110126148
Total current assets5193791496123311683185666311,146
Goodwill11111111———
Total assets5597841636263801943305781,0631,640
Deferred revenue (current)000———00112117
Total current liabilities172839848865535491154268
Short-term debt———02210————
Long-term debt0002986771100244246745
Total debt00029316877105244246745
Total liabilities1930601241061421351693554151,036
Shareholders' equity3667243951923759161222648604
Net debt (negative = net cash)−25−57−42−83−523−231−261265166263
Shares outstanding57m73m84m109m141m143m146m151m156m155m153m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: TGTX vs TLXASND vs TGTXIONS vs TGTXRARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from TG Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to TG Therapeutics, Inc.